AICAR Dosing & Reconstitution Guide

AICAR is typically administered via subcutaneous injection, with a dosing frequency of once daily. Research indicates a dose range of 1000 to 5000 mcg per injection, allowing for flexibility based on specific study designs and objectives. The recommended cycle length for AICAR use is between 8 to 12 weeks, followed by a break of 4 to 8 weeks to assess the compound's effects and mitigate potential tolerance. Timing of administration is often suggested in the morning or approximately 30 to 60 minutes prior to exercise to maximize its metabolic benefits, although individual study designs may vary.

For research purposes, AICAR is typically supplied in a 50 mg vial format. To achieve the desired concentration for experimental use, the recommended reconstitution involves adding 3 mL of sterile water to the vial. This results in a concentration of 16.7 mg/mL, which facilitates precise dosing for various experimental protocols. It is essential to ensure that the reconstitution is conducted under appropriate laboratory conditions to maintain the integrity of the compound and prevent contamination.

The titration schedule for AICAR is designed to gradually increase the dosage over a specified period to assess tolerance and effect. Initial dosing typically begins at 1000 mcg once daily for the first two weeks, followed by an increase to 2000 mcg per day for weeks 3 and 4. Subsequently, the dosage can be escalated to 3000 mcg daily during weeks 5 to 8. For advanced users, the regimen may extend to 4000 to 5000 mcg once daily after week 9. This structured approach allows researchers to evaluate the compound's effects while minimizing the risk of adverse reactions.

Proper storage of AICAR is crucial to maintain its stability and efficacy. In its lyophilized form, AICAR should be stored at room temperature, shielded from moisture, and can remain viable for up to 24 months under these conditions. Once reconstituted, however, the compound must be refrigerated at a temperature range of 2 to 8 °C and is recommended for use within 21 days. Adhering to these storage guidelines can help prevent degradation and ensure reliable results in research applications.

For subcutaneous administration of AICAR, common injection sites include the abdomen and the outer thigh. These locations are selected based on their accessibility and the ability to provide consistent absorption rates. Researchers should consider rotating injection sites to minimize local tissue irritation and ensure optimal delivery of the compound. Careful attention to injection techniques can further enhance the reliability of dosing in experimental settings.

Safety data from clinical trials involving intravenous administration of acadesine (AICAR) indicate that potential side effects may include transient hyperuricemia and mild hypoglycemia, particularly at higher doses. Injection site reactions have also been reported with subcutaneous administration. Additionally, there exists a theoretical risk of lactic acidosis associated with excessive activation of AMP-activated protein kinase (AMPK). Contraindications for AICAR include pre-existing hypoglycemia or diabetes managed with insulin or sulfonylureas due to the potential for additive glucose-lowering effects. Individuals with severe hepatic impairment or conditions such as gout or hyperuricemia should also exercise caution, as AICAR has been shown to elevate uric acid levels.